Nav: Home

Peptide papers point to new ways of tackling bacteria

January 28, 2019

A team of researchers have solved a 20-year riddle of how a crucial step in the biosynthesis of 'last-resort' antibiotics occurs.

In two recent papers published in prestigious journals, the researchers, led by Monash Biomedicine Discovery Institute's Associate Professor Max Cryle, have opened the way to potentially redesigning the antibiotics by altering the peptide assembly involved. This work is linked by a common enzymatic machinery that has great potential to produce highly complex bioactive molecules.

In a study published today in the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS), the team of Monash BDI researchers structurally characterised the peptide bond forming domain in the enzyme 'Ebony' for the first time. Ebony - which is related to the machineries that produce peptide antibiotics in bacteria - plays a central role in the regulation of the neurotransmitters dopamine and histamine in Drosophila. Deletion of Ebony affects external pigmentation but has also been found to alter important functions like vision and circadian regulation.

The study is expected to generate widespread interest in the scientific community from scientists studying protein structure and function, bioengineers and researchers interested in mechanisms of neurotransmitter regulation.

"Ebony is a rare example of a non-ribosomal peptide synthetase (NRPS) from a higher eukaryote," Associate Professor Cryle said, who is also a member of EMBL Australia and the ARC Centre of Excellence in Advanced Molecular Imaging.

"We showed it contains novel types of condensation domain for a NRPS and explained the structure, function and relationship of this enzyme for the first time," he said.

"Ebony helps to moderate the activity of potential neurotransmitters by inactivating them very quickly when required, and also is able to behave differently with different neurotransmitters in a tissue-dependant manner."

Although this domain appears confined to Drosophila, examples of enzymes related to Ebony have been identified in plants and vertebrates, he said.

"Beyond the interest for neural signalling, this system could be used as an interesting example of taking a eukaryotic enzyme and exploiting it in a bacterial system to make new bioactive compounds."

The rate at which this process works is about 60,000 times faster than that used in the bacteria in the complementary study on peptide-based condensation domains, where specificity is more important than speed.

The team published their findings on the glycopeptide antibiotic biosynthesis of vancomycin and teicoplanin-type antibiotics in the journal Chemical Science late last year.

It sought to reconcile two conflicting hypotheses on the process that had previously been generated based on different approaches - in vitro and in vivo.

"These peptide antibiotics are in clinical use so it's important to understand how they're made," Associate Professor Cryle said.

"This is a prerequisite for re-engineering the biosynthetic machinery to make new ones," he said.

Associate Professor Cryle's team collaborated with the German scientists who concentrated on in vivo approaches, and found that the different approaches used were looking at the biosynthetic machinery working at different rates, and hence affecting the outcomes of each experiment.

"These results show how critical the timing of peptide assembly is to the effective production of these antibiotics, and establishes guidelines for re-engineering efforts to produce new, effective antibiotics," he said.

"That's very important given the rise in antibiotic resistance, which is now recognised as a serious problem."

These two studies have improved our understanding of how the enzymatic machinery that produces many important bioactive peptides ensures the exquisite selectivity naturally found in such assembly lines.

More importantly, it shows ways in which such machineries can be effectively redesigned to produce new, more effective compounds. Many important clinical antibiotics are produced through these machineries. With the threat of antimicrobial resistance looming ever larger, there has never been a greater need to be able to alter these biosynthetic processes to generate new, highly active compounds to control infection. These two studies provide important steps along the road to this goal.
-end-
First author of the PNAS study was Dr Thierry Izore, who conducted the crystallography experiments at the centre of this research. Read the full PNAS paper titled The Drosophila melanogaster non-ribosomal peptide synthetase Ebony encodes a novel condensation domain.

First author on the Chemical Science paper was Melanie Schoppet from the Monash BDI. The German research groups were led by Dr Evi Stegmann, University of Tuebingen, and Professor Roderich Sussmuth, Technical University of Berlin. Read the full Chemical Science paper titled The biosynthetic implications of late-stage condensation domain selectivity during glycopeptide antibiotic biosynthesis.

Associate Professor Cryle's research on the Chemical Science paper was supported by the ARC, NHMRC and Universities Australia/DAAD. The PNAS paper was supported by EMBL Australia and the NHMRC.

About the Monash Biomedicine Discovery Institute

Committed to making the discoveries that will relieve the future burden of disease, the newly established Monash Biomedicine Discovery Institute at Monash University brings together more than 120 internationally-renowned research teams. Our researchers are supported by world-class technology and infrastructure, and partner with industry, clinicians and researchers internationally to enhance lives through discovery.

Monash University

Related Bacteria Articles:

How bees live with bacteria
More than 90 percent of all bee species are not organized in colonies, but fight their way through life alone.
The bacteria building your baby
Australian researchers have laid to rest a longstanding controversy: is the womb sterile?
Detecting bacteria in space
A new genomic approach provides a glimpse into the diverse bacterial ecosystem on the International Space Station.
Hopping bacteria
Scientists have long known that key models of bacterial movement in real-world conditions are flawed.
Bacteria uses viral weapon against other bacteria
Bacterial cells use both a virus -- traditionally thought to be an enemy -- and a prehistoric viral protein to kill other bacteria that competes with it for food according to an international team of researchers who believe this has potential implications for future infectious disease treatment.
Drug diversity in bacteria
Bacteria produce a cocktail of various bioactive natural products in order to survive in hostile environments with competing (micro)organisms.
Bacteria walk (a bit) like we do
EPFL biophysicists have been able to directly study the way bacteria move on surfaces, revealing a molecular machinery reminiscent of motor reflexes.
Using bacteria to create a water filter that kills bacteria
Engineers have created a bacteria-filtering membrane using graphene oxide and bacterial nanocellulose.
Probiotics are not always 'good bacteria'
Researchers from the Cockrell School of Engineering were able to shed light on a part of the human body - the digestive system -- where many questions remain unanswered.
A chink in bacteria's armor
Scientists have untangled the structure of a recently discovered bacterial wall-building protein, found in nearly all bacteria.
More Bacteria News and Bacteria Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.